Lifecore Biomedical, Inc. (LFCR)
| Market Cap | 178.77M -21.9% |
| Revenue (ttm) | n/a +0.5% |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 37.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 177,345 |
| Open | 4.990 |
| Previous Close | 4.960 |
| Day's Range | 4.745 - 4.995 |
| 52-Week Range | 3.625 - 8.980 |
| Beta | 1.08 |
| Analysts | Buy |
| Price Target | 6.00 (+25.79%) |
| Earnings Date | May 6, 2026 |
About LFCR
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk... [Read more]
Financial Performance
In 2025, Lifecore Biomedical's revenue was $129.46 million, an increase of 0.46% compared to the previous year's $128.87 million. Losses were -$34.50 million, -22.22% less than in 2025.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for LFCR stock is "Buy." The 12-month stock price target is $6.0, which is an increase of 25.79% from the latest price.
News
Lifecore reports Q1 EPS (43c), consensus (29c)
Reports Q1 revenue $23.19M, consensus $25.96M. “During the first quarter, Lifecore (LFCR) continued to successfully execute the three pillars of its growth strategy – maximizing our existing commercia...
Lifecore Biomedical Earnings Call Transcript: Q1 2026
Q1 2026 saw a 34% revenue decline year-over-year, but cost reductions and new business wins support reaffirmed 2026 guidance. Strong pipeline growth, especially in prefilled syringes, and positive cash flow position the company for a stronger second half.
Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate Update
-- Reaffirms 2026 Guidance -- -- Signed Three New Commercial Site Transfer Programs in First Quarter 2026 -- -- Cost Containment Initiatives Continue to Drive Down Expenses -- Conference Call Today at...
Lifecore Biomedical to Report Financial Results for the First Quarter Ended March 31, 2026, on May 6, 2026
CHASKA, Minn., April 29, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), ...
Lifecore price target raised to $6 from $5.50 at Barrington
Barrington raised the firm’s price target on Lifecore (LFCR) to $6 from $5.50 and keeps an Outperform rating on the shares after meeting with management. The company “repeatedly suggested last
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CHASKA, Minn., April 22, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO”), tod...
Lifecore Biomedical to Participate at 12th Annual American Biomanufacturing Summit
CHASKA, Minn., April 08, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), to...
Lifecore signs two CDMO service agreements with biopharmaceutical customer
Lifecore (LFCR) announced that it has signed two CDMO manufacturing service agreements with an existing U.S. biopharmaceutical customer. This customer is a publicly traded U.S.-based pharmaceutical co...
Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer
-- Site Transfer Agreement for the Manufacture of Commercially Marketed Product -- -- Second Agreement Supports the Expansion of Product Commercially Manufactured at Lifecore to a New Delivery System ...
Lifecore signs CDMO manufacturing services agreement with aesthetics customer
Lifecore (LFCR) announced that it has signed a CDMO manufacturing services agreement with a new aesthetics customer for an established, market-approved product. Under the terms of the agreement, Lifec...
Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company
-- Agreement for the Commercial Manufacture of Established, Approved Aesthetic Product -- -- Third Commercial Site Transfer Agreement Win in Five Months -- -- Program Expected to Generate Commercial R...
Lifecore price target lowered to $5 from $8.50 at Stephens
Stephens analyst Steven Etoch lowered the firm’s price target on Lifecore (LFCR) to $5 from $8.50 and keeps an Equal Weight rating on the shares. The company reported a “solid”
Lifecore Biomedical Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
The company has transformed into a pure-play life sciences CDMO, focusing on sterile injectables and hyaluronic acid fermentation. With reinforced mid-term revenue and margin targets, a robust late-stage pipeline, and new tech transfer agreements, growth is driven by reshoring trends and expanding partnerships. Capacity utilization and operational efficiency are set to improve through 2029.
Lifecore upgraded to Outperform from Market Perform at Barrington
Barrington upgraded Lifecore (LFCR) to Outperform from Market Perform with a $5.50 price target While the firm now thinks 2028, rather than 2027, will represent “the breakout year for Lifecore,”
Lifecore Biomedical Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Lifecore Biomedical, Inc. The investigation focuses on Lifecore Biomedica...
Lifecore Biomedical Transcript: Transition period
Revenue and EBITDA margins grew strongly in 2025, driven by pipeline expansion, operational efficiencies, and new business wins. 2026 guidance anticipates stable revenue and margin progression, with significant growth expected from 2027 as major customer demand and late-stage pipeline launches accelerate.
Lifecore sees ‘modest’ revenue growth in 2027
Lifecore (LFCR) expects to generate modest revenue growth in 2027, with significant revenue growth continuing into 2028. Through 2029, Lifecore’s strategies are expected to achieve sustained growth, r...
Lifecore reports Q4 EPS (16c), consensus (16c)
Reports Q4 revenue $35.75M, consensus $35.15M. The company said: “2025 was a highly productive year for Lifecore (LFCR) Biomedical, during which we strengthened our pipeline, leadership, and standing ...
Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update
-- Recorded Fourth Quarter Revenues of $35.7 Million and Transition Period Revenues of $75.5 Million -- -- Multiple New Programs Signed in Fourth Quarter 2025 Including Two Commercial Site Transfer P...
Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum
CHASKA, Minn., March 10, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), to...
Lifecore Biomedical to Report Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, on March 16, 2026
CHASKA, Minn., March 09, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), to...
Lifecore, Indomo enter DT-001 development services agreement
Lifecore (LFCR) and Indomo announced that the companies have entered into a new development services agreement through which Lifecore will provide Indomo with a range of CDMO services to support
Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment
Indomo Developing Fast-Acting, At-Home Treatment for Inflammatory Acne Lesions to be Administered with the ClearPen ™ , its Proprietary Intradermal Self-Injection Device Lifecore to Manufacture Drug B...
Lifecore Biomedical to Participate at DCAT Week 2026
CHASKA, Minn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), tod...
HALPER SADEH LLC ENCOURAGES LIFECORE BIOMEDICAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is invest...